IP Library Granted Patent US 11,395,692
Granted Patent B2
US 11,395,692 · App. 16/556,616 · Granted Jul 26, 2022

Methods and apparatus for pumping coolant to an energy delivery device

Inventors: Craig Robert Bockenstedt (Bothell, WA); Gregory T. Wing (Carnation, WA)
Assignee: Bausch Health Ireland Limited
A61B18/02A61B18/1206A61B18/18A61B2018/00452A61B2018/00642A61B2018/00791A61B2018/126A61B2018/128A61B2018/1253A61B2018/1266
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,395,692
App. No.
16/556,616
Granted
Jul 26, 2022
Kind
B2
Abstract

Apparatus and methods for delivering coolant to an energy delivery device used to treat tissue with electromagnetic energy. A cooling system includes a pump that is configured to pump a coolant to the energy delivery device.

Claims (35)

1. A method for treating tissue beneath a skin surface with electromagnetic energy, the method comprising:

pumping a fluid from a container to an energy delivery device configured to emit the electromagnetic energy, wherein the container is coupled with a manifold and a pressure sensor is tapped into the manifold;

heating the fluid inside the container to a selected temperature, wherein the fluid is maintained in a liquid state inside the container; and

providing closed-loop control over the heating of the fluid based on pressure readings from the pressure sensor.

2. The method of claim 1 wherein the fluid is pumped from the container to the energy delivery device using a diaphragm pump.

3. The method of claim 2 wherein the fluid is pumped from the container to the energy delivery device using a first line upstream of the diaphragm pump and a second line downstream of the diaphragm pump, the first line is at a first pressure, and the second line is at a second pressure.

4. The method of claim 3 wherein the first pressure is in a range from about 50 psi to about 80 psi, and the second pressure is in range from about 110 psi to about 130 psi.

5. The method of claim 3 wherein the second pressure is greater than the first pressure.

6. The method of claim 1 wherein the fluid is pumped from the container to the energy delivery device using a diaphragm pump, the diaphragm pump is coupled to the container by a fluid line, and the fluid is also maintained under pressure in a liquid state inside the fluid line.

7. The method of claim 1 wherein the fluid is a coolant.

8. The method of claim 7 wherein the energy delivery device includes an electrode, and further comprising:

delivering a spray of the coolant from a nozzle onto the electrode.

9. The method of claim 1 further comprising:

delivering the electromagnetic energy from the energy delivery device to treat the tissue beneath the skin surface.

10. An apparatus for treating tissue beneath a skin surface with electromagnetic energy, the apparatus comprising:

a heater;

a container configured to hold a coolant, the container at least partially enclosed in the heater;

an energy delivery device configured to deliver the electromagnetic energy to the tissue;

a manifold coupling the container with a fluid line;

a cooling system including a pump configured to pump the coolant to the energy delivery device, the pump coupled to the container by the fluid line;

a system controller communicatively coupled to the energy delivery device and to the cooling system, the system controller programmed to control operation of the pump and the heater to maintain the coolant in a liquid state inside the container; and

a pressure sensor communicatively coupled to the system controller, the pressure sensor coupled with the manifold, and the pressure sensor tapped into the manifold,

wherein the system controller is configured to control the operation of the heater and the pump based on pressure readings from the pressure sensor.

11. The apparatus of claim 10 wherein the system controller is programmed to control the operation of the heater and the pump to maintain the coolant in the liquid state inside the fluid line.

12. The apparatus of claim 10 wherein the energy delivery device includes an electrode, a nozzle, and a control valve configured to control delivery of the coolant from the nozzle to the electrode.

13. The apparatus of claim 12 wherein the pump is a diaphragm pump.

14. The apparatus of claim 13 further comprising:

a manifold arranged between the pump and the control valve, the manifold including an arrestor configured to respond to pressure surges from operation of the diaphragm pump.

15. The apparatus of claim 12 wherein the energy delivery device is configured to emit the electromagnetic energy from the electrode.

16. The apparatus of claim 10 further comprising:

a first check valve in the fluid line.

17. The apparatus of claim 16 further comprising:

a second check valve in the fluid line.

18. The apparatus of claim 14 further comprising:

a check valve in the fluid line.

Assignments (12)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: SOLTA MEDICAL IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0394 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
CONFIRMATORY PATENTS ASSIGNMENT Recorded Jan 11, 2023
From: BAUSCH HEALTH IRELAND LIMITED
To: SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 062352/0396 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 4, 2020
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; DOW PHARMACEUTICAL SCIENCES, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; BAUSCH HEALTH US, LLC; SANTARUS, INC.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT FOR THE NOTEHOLDER SECURED PARTIES
Reel/Frame 051797/0491 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 4, 2020
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; DOW PHARMACEUTICAL SCIENCES, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; BAUSCH HEALTH US, LLC; SANTARUS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 051797/0416 →
Continuity (2)
Provisional Application 62725562 · Aug 31, 2018
Related Publication 20200069354A1 · Mar 5, 2020